Review



dmso  (Biotium)


Bioz Verified Symbol Biotium is a verified supplier
Bioz Manufacturer Symbol Biotium manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Biotium dmso
    Dmso, supplied by Biotium, used in various techniques. Bioz Stars score: 94/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dmso/product/Biotium
    Average 94 stars, based on 22 article reviews
    dmso - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    96
    MedChemExpress dimethyl sulfoxide dmso
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dimethyl Sulfoxide Dmso, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dimethyl sulfoxide dmso/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    dimethyl sulfoxide dmso - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    94
    Biotium dmso
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dmso, supplied by Biotium, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dmso/product/Biotium
    Average 94 stars, based on 1 article reviews
    dmso - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Merck & Co dimethyl sulfoxide (dmso, 99.5
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dimethyl Sulfoxide (Dmso, 99.5, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dimethyl sulfoxide (dmso, 99.5/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    dimethyl sulfoxide (dmso, 99.5 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Merck & Co dmso
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dmso, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dmso/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    dmso - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    96
    MedChemExpress dimethyl sulfoxide dmso vehicle
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dimethyl Sulfoxide Dmso Vehicle, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dimethyl sulfoxide dmso vehicle/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    dimethyl sulfoxide dmso vehicle - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    99
    Vazyme Biotech Co rapid taq master mix vazyme p222 02 tritonx 100 sigma aldrich t8787 dmso mpbio 196055 vectashield
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Rapid Taq Master Mix Vazyme P222 02 Tritonx 100 Sigma Aldrich T8787 Dmso Mpbio 196055 Vectashield, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rapid taq master mix vazyme p222 02 tritonx 100 sigma aldrich t8787 dmso mpbio 196055 vectashield/product/Vazyme Biotech Co
    Average 99 stars, based on 1 article reviews
    rapid taq master mix vazyme p222 02 tritonx 100 sigma aldrich t8787 dmso mpbio 196055 vectashield - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    MedChemExpress dmso
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Dmso, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dmso/product/MedChemExpress
    Average 99 stars, based on 1 article reviews
    dmso - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    96
    Valiant Co Ltd cryoprestm dimethyl sulfoxide
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    Cryoprestm Dimethyl Sulfoxide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryoprestm dimethyl sulfoxide/product/Valiant Co Ltd
    Average 96 stars, based on 1 article reviews
    cryoprestm dimethyl sulfoxide - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    MedChemExpress v v dimethyl sulfoxide dmso vehicle control
    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with <t>DMSO,</t> <t>Z-VAD-FMK,</t> NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
    V V Dimethyl Sulfoxide Dmso Vehicle Control, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v v dimethyl sulfoxide dmso vehicle control/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    v v dimethyl sulfoxide dmso vehicle control - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    Image Search Results


    Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with DMSO, Z-VAD-FMK, NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.

    Journal: Poultry Science

    Article Title: RACK1 inhibits fowl adenovirus serotype 4 replication by targeting the viral protein Hexon for ubiquitin-proteasome degradation

    doi: 10.1016/j.psj.2026.106627

    Figure Lengend Snippet: Interaction with RACK1 targets Hexon for degradation through the ubiquitin-proteasome pathway. ( A ) LMH cells were co-transfected with Flag-Hexon (2 µg) and Myc-RACK1 (2 µg) for different time (24 and 48 h). After transfection, the cell lysates were harvested and examined by Western blotting. ( B ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 (0.4 or 2 µg) for 24 h. After transfection, the cell lysates were harvested and examined by Western blotting. ( C ) The relative expression levels of Flag-Hexon in panel A. ( D ) The relative expression levels of Flag-Hexon in panel B. ( E ) LMH cells were co-transfected with Flag-Hexon and Myc-RACK1 or Flag-Hexon and empty vector. At 24 h post transfection, cells were treated with cycloheximide (CHX, 50 μg/mL) at different time points (0, 2, 4, 6, and 8 h) before being harvested. Cell lysates were prepared and examined by Western blotting using the indicated antibodies. (F ) The relative expression levels of Flag-Hexon in panel E. ( G ) LMH cells were pretreated with DMSO, Z-VAD-FMK, NH 4 Cl for 2 h, followed by co-transfection with Flag-Hexon and Myc-RACK1 for 24 h in the presence of the respective inhibitors. Cell lysates were prepared and examined with Western blotting using the indicated antibodies. For MG132 (10 μM), cells were not pretreated; instead, this inhibitor was added to the culture medium 12 h prior to sample collection. ( H ) The relative expression levels of Flag-Hexon in panel G. Data are representative of three independent experiments and presented as means ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.

    Article Snippet: Dimethyl sulfoxide (DMSO), Z-VAD-FMK, MG132, BafA1, NH 4 Cl were purchased from MedChemExpress (MCE, China).

    Techniques: Ubiquitin Proteomics, Transfection, Western Blot, Expressing, Plasmid Preparation, Cotransfection